文献速递产科母胎医学

纵向评估血管生成标志物预测确诊子痫前期孕妇不良结局

Longitudinal assessment of angiogenic markers in prediction of adverse outcome in women with confirmed pre-eclampsia.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

该回顾性分析基于2013年1月至2020年12月维也纳医科大学前瞻性收集的数据,纳入323例确诊子痫前期且至少两次检测血管生成标志物的单胎孕妇,共885次检测。纵向sFlt-1/PlGF比值对复合不良母亲结局的AUC为0.72,对复合不良围产结局的AUC为0.82,均优于部分常规实验室指标。结论认为纵向血管生成标志物评估是良好的预测工具,需进一步研究最佳监测方案。

要点

  • 确诊子痫前期孕妇纵向sFlt-1/PlGF比值预测复合不良母亲结局AUC为0.72。
  • 纵向sFlt-1/PlGF比值预测复合不良围产结局AUC为0.82,优于肌酐。
  • 联合LDH、肌酐和sFlt-1/PlGF比值预测母亲结局AUC为0.77,显著优于单用比值。

核心结论

  • 在确诊子痫前期的妊娠中,纵向母亲血清血管生成标志物评估是母亲和围产不良结局的良好预测指标,优于某些常规实验室参数。
  • 进一步研究应关注子痫前期诊断后的最佳监测方案。

研究设计与样本

  • 本研究为回顾性分析,数据来自2013年1月至2020年12月维也纳医科大学前瞻性收集的资料。
  • 纳入标准为单胎妊娠、确诊子痫前期且诊断后至少两个时间点进行母亲血清血管生成标志物评估。
  • 共纳入323例确诊子痫前期孕妇,获得885次诊断后sFlt-1/PlGF比值测量。

主要发现

  • 复合不良母亲结局包括重症监护室入住、肺水肿、子痫和/或死亡;复合不良围产结局包括死产、新生儿死亡、胎盘早剥、新生儿重症监护室入住、脑室内出血、坏死性小肠结肠炎、呼吸窘迫综合征和/或机械通气支持。
  • 预测复合不良母亲结局:sFlt-1/PlGF比值AUC为0.72(95%CI 0.62-0.81),肌酐AUC为0.71(95%CI 0.62-0.81),LDH AUC为0.73(95%CI 0.65-0.81);血小板AUC为0.65(95%CI 0.55-0.74),ALT AUC为0.59(95%CI 0.49-0.69),AST AUC为0.61(95%CI 0.51-0.71)。
  • 预测复合不良母亲结局的最佳模型为LDH、肌酐和sFlt-1/PlGF比值联合,AUC为0.77(95%CI 0.68-0.85),显著高于单用sFlt-1/PlGF比值(P=0.037)。
  • 预测复合不良围产结局:sFlt-1/PlGF比值AUC为0.82(95%CI 0.75-0.89),肌酐AUC为0.74(95%CI 0.67-0.80),sFlt-1/PlGF比值优于单用肌酐(P<0.001);LDH AUC为0.65(95%CI 0.53-0.74),血小板AUC为0.57(95%CI 0.44-0.67),ALT AUC为0.58(95%CI 0.48-0.67),AST AUC为0.58(95%CI 0.48-0.67)。
  • 预测复合不良围产结局时,没有任何生物标志物组合优于单用sFlt-1/PlGF比值(所有P>0.05)。

临床怎么用

  • 原文结论认为纵向母亲血清血管生成标志物评估是确诊子痫前期妊娠中母亲和围产不良结局的良好预测指标,优于某些常规实验室参数。
  • 原文结论指出进一步研究应关注子痫前期诊断后的最佳监测方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Angiogenic marker assessment, such as the ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF), is known to be a useful tool in the prediction of pre-eclampsia (PE). However, evidence from surveillance strategies in pregnancies with a PE diagnosis is lacking. Therefore, we aimed to assess the predictive performance of longitudinal maternal serum angiogenic marker assessment for both maternal and perinatal adverse outcomes when compared to standard laboratory parameters in pregnancies with confirmed PE. METHODS: This was a retrospective analysis of prospectively collected data from January 2013 to December 2020 at the Medical University of Vienna. The inclusion criteria were singleton pregnancy with confirmed PE and post-diagnosis maternal serum angiogenic marker assessment at a minimum of two timepoints. The primary outcome was the predictive performance of longitudinal sFlt-1 and PlGF assessment for adverse maternal and perinatal outcomes compared to conventional laboratory monitoring at the same time in pregnancies with confirmed PE. Composite adverse maternal outcome included intensive care unit admission, pulmonary edema, eclampsia and/or death. Composite adverse perinatal outcome included stillbirth, neonatal death, placental abruption, neonatal intensive care unit admission, intraventricular hemorrhage, necrotizing enterocolitis, respiratory distress syndrome and/or mechanical ventilator support. RESULTS: In total, 885 post-diagnosis sFlt-1/PlGF ratio measurements were obtained from 323 pregnant women with confirmed PE. For composite adverse maternal outcome, the highest standalone predictive accuracy was obtained using maternal serum sFlt-1/PlGF ratio (area under the receiver-operating-characteristics curve (AUC), 0.72 (95% CI, 0.62-0.81)), creatinine (AUC, 0.71 (95% CI, 0.62-0.81)) and lactate dehydrogenase (LDH) levels (AUC, 0.73 (95% CI, 0.65-0.81)). Maternal platelet levels (AUC, 0.65 (95% CI, 0.55-0.74)), serum alanine aminotransferase (ALT) (AUC, 0.59 (95% CI, 0.49-0.69)) and aspartate aminotransferase (AST) (AUC, 0.61 (95% CI, 0.51-0.71) levels had poor standalone predictive accuracy. The best prediction model consisted of a combination of maternal serum LDH, creatinine levels and sFlt-1/PlGF ratio, which had an AUC of 0.77 (95% CI, 0.68-0.85), significantly higher than sFlt-1/PlGF ratio alone (P = 0.037). For composite adverse perinatal outcome, the highest standalone predictive accuracy was obtained using maternal serum sFlt-1/PlGF ratio (AUC, 0.82 (95% CI, 0.75-0.89)) and creatinine (AUC, 0.74 (95% CI, 0.67-0.80)) levels, sFlt-1/PlGF ratio being superior to creatinine alone (P < 0.001). Maternal serum LDH levels (AUC, 0.65 (95% CI, 0.53-0.74)), platelet count (AUC, 0.57 (95% CI, 0.44-0.67)), ALT (AUC, 0.58 (95% CI, 0.48-0.67)) and AST (AUC, 0.58 (95% CI, 0.48-0.67)) levels had poor standalone predictive accuracy. No combination of biomarkers was superior to maternal serum sFlt-1/PlGF ratio alone for prediction of composite adverse perinatal outcome (P > 0.05 for all). CONCLUSIONS: In pregnancies with confirmed PE, longitudinal maternal serum angiogenic marker assessment is a good predictor of adverse maternal and perinatal outcomes and superior to some conventional laboratory parameters. Further studies should focus on optimal surveillance following diagnosis of PE. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Binder J, Palmrich P, Kalafat E, et al. Longitudinal assessment of angiogenic markers in prediction of adverse outcome in women with confirmed pre-eclampsia. Ultrasound Obstet Gynecol. 2023. PMID: 37265117. doi:10.1002/uog.26276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。